Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?

In this study we compared the diagnostic utility of: (1) neuron-specific enolase (NSE); (2) squamous cell carcinoma antigen (SCC); (3) carcinoembryonic antigen (CEA); and (4) cytokeratin markers (CYFRA 21-1, TPA, TPM, TPS) in patients with small-cell lung cancer (SCLC) (21 cases) and non-small-cell lung cancer (94 cases). For comparison we also studied 66 patients with benign lung diseases and nine with pleural mesothelioma. NSE levels in SCLC patients were significantly higher than those in all the other groups studied. No significant variations were found among the SCC levels in all groups. CEA levels in patients with adenocarcinoma were significantly higher than those in all other groups studied. CYFRA 21-1 serum levels significantly increased in patients with squamous cell carcinoma and mesothelioma, while TPA, TPS and TPM increased in patients with lung cancer irrespective of the histological type. In patients with SCLC, high levels of all markers except SCC were found when the disease was extensive. In patients with non-SCLC, the highest levels of all tumour markers were usually found in those with advanced disease, although CYFRA 21-1 gave a sensitivity of 44% when a specificity of 95% was fixed in stage I non-SCLC patients. An analysis of receiver operating characteristic curves revealed that the highest diagnostic accuracies in distinguishing benign from malignant lung diseases were achieved with TPM (81%), CYFRA 21-1 (72%), CEA (78%) or TPA (78%) when using cut-off values of 46 Ul-1, 3.0 micrograms l-1, 2.0 micrograms l-1 and 75 Ul-1 respectively. When all patients were considered, the combined evaluation of more than one marker did not significantly improve the results obtained with TPM alone. However, taking into consideration the fact that CYFRA 21-1 is the most sensitive index of early lung tumours and that its combined determination with TPM did not worsen the overall sensitivity and specificity of the latter, the combined use of these two markers may be suggested as a useful took for the diagnosis of lung tumours.

[1]  H. Dienemann,et al.  Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[2]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[3]  P. Knekt,et al.  Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening , 1993, Cancer.

[4]  J. Daurès,et al.  Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. , 1993, Cancer research.

[5]  B. G. Blijenberg,et al.  Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. , 1994, British Journal of Cancer.

[6]  H. Dienemann,et al.  Comparison of Cytokeratin Fragment 19 (CYFRA 21-1), Tissue Polypeptide Antigen (TPA) and Tissue Polypeptide Specific Antigen (TPS) as Tumour Markers in Lung Cancer , 1993, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[7]  H Dienemann,et al.  CYFRA 21‐1: A new marker in lung cancer , 1993, Cancer.

[8]  S. Kaye,et al.  Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? , 1990, British Journal of Cancer.

[9]  S. Tseng,et al.  Keratin classes: molecular markers for different types of epithelial differentiation. , 1983, The Journal of investigative dermatology.

[10]  Y. Mizushima,et al.  Clinical evaluation of five tumor marker assay in patients with lung cancer. , 1991, Anticancer research.

[11]  Carney,et al.  Lung Cancer Biology. , 1995, Seminars in radiation oncology.

[12]  S. Wagenaar,et al.  Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. , 1988, Cancer research.

[13]  A. Fasoli.  [Clinical decision analysis]. , 1986, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

[14]  E. Lazarides.  Intermediate filaments as mechanical integrators of cellular space , 1980, Nature.

[15]  B. Bergman,et al.  Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. , 1993, European journal of cancer.

[16]  H. Hansen,et al.  Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). , 1992, British Journal of Cancer.